Gritstone Jumps Into COVID-19 Vaccine Race, Eyeing Mutant Strains
Potentially Resistant Strains Raise Worries
The company is developing a vaccine with both adenoviral and mRNA technology that could potentially overcome resistance mutations on the SARS-CoV-2 spike protein.
You may also be interested in...
Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.